Kazuhiko Yoshida

Tokyo Women's Medical University — Japan

Medicine · Health Sciences

43h-index8.2kcitations582works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(194), Bladder and Urothelial Cancer Treatments(95), Renal and related cancers(63), Cancer Immunotherapy and Biomarkers(61), Renal and Vascular Pathologies(35)

Publications577 total

Four-dimensional parametric and dual-time-point FDG-PET/CT imaging in metabolically active renal cell carcinoma: a comparison of clear cell and non-clear cell carcinoma
Nuclear Medicine Communications·2026
Outcomes of tyrosine kinase inhibitor monotherapy for advanced renal cell carcinoma arising in patients with kidney transplantation: comparison with sporadic and end-stage renal disease populations
Clinical and Experimental Nephrology·2025
Treatment Profile of First‐Line Immune Checkpoint Inhibitor Combination Therapy for Advanced Renal Cell Carcinoma in Patients With End‐Stage Renal Disease on Dialysis
International Journal of Urology·2025Open Access
Renal Function With Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study in Japan
Anticancer Research·2025
Midterm outcomes of combination therapy with immune checkpoint inhibitors and VEGFR-TKIs in real-world patients with advanced renal cell carcinoma
2025Open Access
Aesthetic Deep Orbital Fat Decompression for Proptosis of Nonthyroidal Origin: A Case Series of 23 Patients
Plastic & Reconstructive Surgery Global Open·2025Open Access
Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma
Japanese Journal of Clinical Oncology·2025
Safety of Enfortumab Vedotin Plus Pembrolizumab in Hemodialysis Patients With Metastatic Urothelial Carcinoma: Case Report
Cancer Diagnosis & Prognosis·2025· 1 citedOpen Access
Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis
International Urology and Nephrology·2025
Impact of Polypharmacy on Perioperative Outcomes of Robot-assisted Laparoscopic Partial Nephrectomy for Small Renal Masses
In Vivo·2025Open Access
Outcomes of Enfortumab Vedotin Treatment in Patients Ineligible for the EV-301 Trial
In Vivo·2025Open Access
Case Report: complete response to preoperative ipilimumab and nivolumab combination therapy in advanced papillary renal cell carcinoma with inferior vena cava tumor thrombus and multiple metastases
Frontiers in Oncology·2025Open Access
Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma
Urologic Oncology Seminars and Original Investigations·2025· 3 cited
Association between enfortumab vedotin and renal function in metastatic urothelial carcinoma: A multicenter retrospective study in Japan
2025Open Access
Effect of age on treatment outcomes of first‐line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma
Geriatrics and gerontology international/Geriatrics & gerontology international·2025
Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study
Japanese Journal of Clinical Oncology·2025· 2 cited
Renal Parenchymal Defects Occasionally Observed in Non–Well-Differentiated Perirenal Liposarcomas Unlike in Well-Differentiated Types
Journal of Computer Assisted Tomography·2025
IP24-04 TREATMENT OUTCOMES OF ENFORTUMAB VEDOTIN IN INELIGIBLE PATIENTS FROM THE EV-301 TRIAL
The Journal of Urology·2025
MP14-13 IMPACT OF BODY COMPOSITION ON OUTCOMES OF IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA
The Journal of Urology·2025
MP02-14 CLINICAL OUTCOMES OF REPEAT PARTIAL NEPHRECTOMY COMPARED TO INITIAL PARTIAL NEPHRECTOMY FOR RENAL CELL CARCINOMA: A PROPENSITY SCORE MATCHING STUDY
The Journal of Urology·2025
page 1 of 29Next →

Frequent Co-authors

Shigeaki Ohno(18), Kazuhiro Ohgami(10), Yoshikazu Koyama(9), Toshio Takagi(9), Kenji Shiratori(8), Iliyana Ilieva(8), Satoru Kase(8), Hirohito Kobayashi(8), Takayuki Harada(7), Tsunenori Kondo(7), Junpei Iizuka(7), Junko Imaki(6), Xue-Hai Jin(5), Yukari Suzuki(5), Kenji Omae(5), Kazunari Tanabe(5), Hidehiko Matsuda(4), Nobuyoshi Kitaichi(4), Hiroki Ishihara(4), Wataru Saito(4)